Literature DB >> 22229519

Monitoring device acceptance in implantable cardioverter defibrillator patients using the Florida Patient Acceptance Survey.

Henneke Versteeg1, Annemieke Starrenburg, Johan Denollet, Job van der Palen, Samuel F Sears, Susanne S Pedersen.   

Abstract

BACKGROUND: Patient device acceptance might be essential in identifying patients at risk for adverse patient-reported outcomes following implantation of an implantable cardioverter defibrillator (ICD). We examined the validity and reliability of the Florida Patient Acceptance Scale (FPAS) and identified correlates of device acceptance in a Dutch cohort of ICD patients.
METHODS: Patients with a first-time ICD (N = 272, mean age = 59.2 ± 11.9, 82% men) recruited from the Erasmus Medical Center, Rotterdam, or the Medisch Spectrum Twente, Enschede, The Netherlands completed the FPAS, the Type D Scale, and the Hospital Anxiety and Depression Scale.
RESULTS: Exploratory and confirmatory factor analyses indicated that eliminating three items from the FPAS, leaving 12 items contributing to three factors, is equivalent to the original four-factor version of the FPAS. The abbreviated FPAS had a high internal consistency both for the total scale and all subscales, with Cronbach's alphas ranging from 0.76 to 0.82. Anxiety (odds ratio [OR]: 9.75; 95% confidence interval [CI]: 2.38-39.87; P = 0.002), depression (OR: 2.96; 95% CI: 0.98-8.93; P = 0.05), and the distressed (Type D) personality (OR: 5.04; 95% CI: 1.50-16.92; P = 0.01), but not demographic and clinical factors including shocks, were significant independent correlates of poor device acceptance.
CONCLUSION: A shortened 12-item, three-factor version of the FPAS was shown to be a valid and internally consistent instrument to assess device acceptance in Dutch ICD patients. Psychological but not clinical factors were the primary correlates of device acceptance, which underlines the importance of taking into account the patient's psychological profile when seeking to identify patients at risk for adjustment difficulties after ICD implantation. ©2012, The Authors. Journal compilation ©2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22229519     DOI: 10.1111/j.1540-8159.2011.03299.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  5 in total

1.  Age, Sex, and Remote Monitoring Differences in Device Acceptance for Patients With Implanted Cardioverter Defibrillators in Canada.

Authors:  Jessica Ng; Samuel F Sears; Derek V Exner; Lucy Reyes; Xenia Cravetchi; Peggy Cassidy; James Morton; Carmen Lohrenz; Aaron Low; Roopinder K Sandhu; Robert S Sheldon; Satish R Raj
Journal:  CJC Open       Date:  2020-06-16

2.  The Predictor Roles of Spiritual Well-Being, Healthcare Professionals' Support and Shock Anxiety in Implantable Cardioverter-Defibrillator Device Acceptance.

Authors:  Nilofar Pasyar; Masoume Rambod; Alireza Zare; Mohammad Hossein Nikoo
Journal:  Malays J Med Sci       Date:  2022-06-28

3.  Embodying a New Meaning of Being At Risk: Living With an Implantable Cardioverter Defibrillator for Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  April Manuel; Fern Brunger
Journal:  Glob Qual Nurs Res       Date:  2016-10-24

4.  Remote monitoring of implantable cardioverter defibrillators: Patient experiences and preferences for follow-up.

Authors:  Ivy Timmermans; Mathias Meine; Istvan Szendey; Johannes Aring; Javier Romero Roldán; Lieselotte van Erven; Philipp Kahlert; Edgar Zitron; Philippe Mabo; Johan Denollet; Henneke Versteeg
Journal:  Pacing Clin Electrophysiol       Date:  2019-01-02       Impact factor: 1.976

5.  The INFluence of Remote monitoring on Anxiety/depRession, quality of lifE, and Device acceptance in ICD patients: a prospective, randomized, controlled, single-center trial.

Authors:  Florian Leppert; Johannes Siebermair; Ulrich Wesemann; Eimo Martens; Stefan M Sattler; Stefan Scholz; Stefan Veith; Wolfgang Greiner; Tienush Rassaf; Stefan Kääb; Reza Wakili
Journal:  Clin Res Cardiol       Date:  2020-05-16       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.